High-throughput technology improves antigen-specific CD4+ T cell profiling in vaccination and autoimmune diseases, indicating broader applications in immunotherapy.
Description Although identification and characterization of antigen-specific CD4+ T cells remains crucial for understanding immune responses, several technique hurdles have made it challenging to do so. Building upon our TetTCR-SeqHD platform, we developed a high-throughput and high-dimensional profiling technology, TetTCRII-SeqHD, for antigen-specific CD4+ T cells. The technology leverages the recently developed affinity enhanced class II MHC tetramer and optimizes the staining conditions to address the inherently lower TCR-pMHC class II binding avidity. Multiple tetramers can be multiplexed to simultaneously track T cells with different antigen specificities. Validation using multiple TCRs with known antigens demonstrated an average of > 90% precision and >80% recall rate, comparable to conventional methods while providing comprehensive transcriptional and phenotypic information at single-cell resolution. This advancement of TetTCRII-SeqHD provides valuable insights into helper T cell responses with broad applications in studying infection, vaccination, autoimmune diseases, and cancer immunotherapy. Funding Sources Supported by NIH U19AI128949 and R33CA256086. Topic Categories Technological Innovations in Immunology (TECH)
No takes yet. Share an insight, caveat, or question.
Jiang et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: